<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Canavan, Neil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Tejpar, Sabine</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Predictive Biomarkers for Response to Cetuximab in Colorectal Cancer: KRAS Marches On</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">4-5</style></pages><abstract><style  face="normal" font="default" size="100%">In the parade of molecules that strives for validation as predictors of therapeutic activity, the oncogene KRAS seems to have found its place in front of the band. This article discusses two studies that examined the utility of this marker in predicting response to cetuximab.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>